| New York, NY, July 15, 2009 – Milestone Venture Partners, an early-stage venture capital firm, today announced that it has invested in IntegriChain, Inc. (“IntegriChain” or the “Company”). Milestone led the Series B financing and was joined by Cross Atlantic Partners. As a result of the financing, Morgan Rodd, General Partner of Milestone, will join IntegriChain’s Board of Directors. New Jersey-based IntegriChain provides the pharmaceutical industry with data collection, integration, enrichment, analysis and reporting of sales and inventory activity. IntegriChain’s data solutions enable its customers to improve sales performance and total pipeline measurement by maximizing transparency and accountability in each customer’s down-stream supply chain. Using proprietary algorithms, IntegriChain enriches raw channel data it receives from its customers and then provides a more granular view with deeper coverage across each customer’s supply chain. IntegriChain delivers its data solutions to its customers on a subscription basis typically with multi-year contracts. The investment in IntegriChain marks the thirteenth investment that Milestone has made out of its current fund, Milestone Venture Partners III. IntegriChain represents the fifth healthcare technology investment Milestone has made out of its current fund and the ninth healthcare technology investment overall. “We invested in IntegriChain because of its explosive growth vector and its outstanding long-term investment potential. Its superior data solutions provide its customers a much more granular and accurate view of what is happening within their supply-chains than other solutions currently in the market,” said Morgan Rodd, General Partner of Milestone. “By using IntegriChain’s data solutions, its existing customers can make more effective business decisions within several key areas, including new product launches, finance, sales forecasting and demand analysis, thereby driving operational efficiencies and improving financial performance across a customer’s entire organization.” “We are pleased to have Milestone as an investor and delighted to have Morgan Rodd join our board,” said Kevin Leininger, CEO of IntegriChain. “We chose to partner with Milestone because of their deep domain expertise in healthcare information technology and their understanding of the healthcare ecosystem. In addition, Milestone has a strong track record of successful investments in the healthcare IT space, and we believe they will add significant value as we continue to build IntegriChain.” About IntegriChain IntegriChain, Inc is a next generation commercial insight provider supporting the pharmaceutical industry. IntegriChain delivers actionable intelligence at a low total cost by combining a customer’s own data with IntegriChain domain expertise and a proprietary platform for rapid analytics deployment. IntegriChain helps manufacturers improve operations and sales performance by providing new levels of transparency to all parts of the supply chain. IntegriChain’s process includes data integration, enrichment, analysis and reporting of sales and inventory activity on a near real-time basis. IntegriChain’s services require no investment in hardware or software. Its services unlock the value of information its clients already own, resulting in exceptional analytical accuracy for market demand data. For more information, visit www.integrichain.com. About Milestone Venture Partners Milestone Venture Partners, located in New York City, is an early-stage venture capital fund with $70 million under management. Milestone’s investment strategy is focused on capital-efficient, technology-enhanced services businesses in the Greater New York region. Areas of expertise include media and marketing services, healthcare IT, and financial services IT. For more information about Milestone, visit www.milestonevp.com. # # # |
